EMA Authorised: Nulibry (fosdenopterin hydrobromide dihydrate) — TMC Pharma (EU) Limited

View source ↗

Summary

The European Medicines Agency authorised Nulibry (fosdenopterin hydrobromide dihydrate) for the treatment of molybdenum cofactor deficiency, an inborn error of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Molybdenum Cofactor Deficiency

Drugs mentioned

• Nulibry (fosdenopterin)

Snippet

Status: Authorised. Therapeutic area: Metal Metabolism, Inborn Errors. MAH: TMC Pharma (EU) Limited. Decision date: 24/07/2024. Orphan medicine